This page belongs to: Action Plan for Critical Technologies
Systems for identifying or designing new types of antibiotic and antiviral drugs that can treat bacterial and viral infections in humans and animals safely and effectively. New antibiotic and antiviral drugs must be continually developed and tested to ensure there are drugs available to treat both new infectious diseases and existing bacterial and viral diseases that become resistant to existing drugs. Examples include drugs to treat Methicillin-resistant Staphylococcus aureus (MRSA) and severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2).
- Education & Research
- Energy & Environment
Estimated impact on national interest
Economic Prosperity - High
National Security - Med
Key Australian Government actions
- Resistance joint initiative – Australia’s National Antimicrobial Resistance Strategy
- National Microbial Genomics Framework 2019-2022
- Medical Research Future Fund (MRFF) Priority Mission
- National Manufacturing Strategy – Priority area of Medical Products
- National Research Infrastructure (NRI) and 2021 NRI Roadmap
- Agricultural Innovation Policy Statement
- Various Rural RDC priority initiatives
- Therapeutic Goods Act 1989
- Therapeutic Goods Regulations 1990
- Defence and Strategic Goods List 2021
- Pandemic preparedness and response
- Improved individual health
- Prevention of disease in livestock and companion animals
- Improved public health outcomes
- Reduced mortality and morbidity from infectious and communicable diseases
- Reduce workforce absenteeism due to infectious and communicable diseases
ANZ Standard Research Classification Category
- Agricultural biotechnology
- Applied computing
- Applied ethics
- Artificial intelligence
- Biochemistry and cell biology
- Bioinformatics and computational biology
- Clinical sciences
- Data management and data science
- Fisheries sciences
- Industrial biotechnology
- Machine learning
- Medical biotechnology
- Plant biology
- Software engineering
- Veterinary sciences
Readiness Level – Now
- Bacteriophage therapy for bacterial infection
- Antibacterial drugs to deal with new bacterial infections or drug resistant bacteria
- Antiviral drugs to deal with new viruses or drug resistant viruses
- New vaccines against emerging viruses
- Dose regimen optimisation to treat critically ill patients
- Needle-free mechanisms of delivery for vaccines against viral and/or bacterial infections
Readiness Level – 2–5 years
- Improved speed and accuracy for identification and characterisation of bacteria and viruses
- Rapid antibacterial and antiviral drug development in response to new or evolving threats
Readiness Level – Beyond 5 years
- New antibiotics and antivirals that act on different cellular structures, proteins or functions
- Personalised antibacterial and antiviral treatments
- Repurposing of existing pharmaceutical compounds for antimicrobial or antiviral use
- Therapeutic application of naturally occurring compounds for antimicrobial or antiviral use
- Broad-spectrum antibacterial and antiviral drug development to treat novel or unforeseen pathogens
Australia's place in the world
The United States has the highest research impact for novel antibiotics and antivirals, with China second, and Australia 8th. China has the highest number of patents in this area, almost double that of the US, with Australia ranking 15th. Venture capital (VC) investment has been increasing steadily at around 8% p.a. The US has a clear lead in VC investment this area, over China and the United Kingdom. Of note, VC investment in Ireland and Israel ranks 4th and 5th respectively. Australia ranks 10th for VC investment.
The top 10 international institutions comprises a number of different countries, with Harvard University (US) and the Institut national de la santé et de la recherche médicale (France) ranked closely in 1st and 2nd. The University of Melbourne (Australia) is ranked 10th. The diversity of countries represented in the top 10 institutions reflects the global significance of antimicrobial resistance and the urgent need for new antibiotics and antivirals.
Antibiotic and antiviral development is an area where Australia performs strongly in research, with five institutes in the international top 50. This capability is supported by our expertise in genomics and genetic engineering, as well as government commitment to international anti-microbial resistance initiatives.
Opportunities and risks
Maintaining Australia’s high standard of living and longevity requires a steady flow of novel antibiotic and antiviral drugs. Every time a person, plant or animal is treated with an antibiotic or antiviral drug there is some risk that the bacteria or virus will develop resistance to that drug. Given enough time the antibiotic and antiviral drugs currently relied on will become less effective or stop working entirely, and infectious diseases that are currently treatable could once again become deadly.As well as protecting Australians from death and disease, novel antibiotics and antivirals have the potential to increase Australia’s economic prosperity. Drugs can be exported from Australia or licenced for sale overseas. More effective antibiotics and antivirals can reduce treatment times and shorten or eliminate costly hospital stays. Antibiotics and antivirals with fewer side effects can get people back to work sooner and attract premium pricing in developed economies. Having a ‘war chest’ of antibiotics and antivirals with different mechanisms of action increases the chances that an effective treatment can be quickly identified and dispensed when a new bacteria or virus emerges to threaten Australian society.
The risks from novel antibiotics and antivirals stem from lacking them when they are needed, and the large amount of time and money that is currently required to discover and develop novel antibiotics and antivirals that are effective and safe to use. Further risks arise from public acceptance. When a safe and effective novel antibiotic or antiviral is approved for use, it likely won’t be widely prescribed right away, limiting and delaying the return on investment for developing the drug and also limiting public access. While this may anger investors and potential patients, it limits the opportunities for drug resistance to arise and ensures the drug is available for when it is truly needed.
Research impact (RI)
The United States has the highest research impact, with Australia ranked 8th. Total volume of published research has increased at around 8% p.a. over the 5 year period 2016–2020, with 23% of research involving international collaboration.
- USA - 34894
- China - 21107
- India - 13455
- UK - 11703
- Italy - 9190
- Australia - 7210
The research impact provides an indication of the productivity of a country or institution. Here, productivity was assumed to be represented by the volume of publications (i.e. scholarly output) as an indicator of the resources & facilities, and the level of interest in the publications as an indicator of quality.
The United States has significantly higher venture capital (VC) investment for novel antibiotics and antivirals, compared to China and the United Kingdom. Australia ranks 10th. Investment in this area has been growing at around 8% p.a. since 2016.
Data from Crunchbase. The Crunchbase database provides a partial view of the global VC landscape. However the quantity, quality and richness of the data are considered to be statistically significant, and indicative of global trends.
Patents - international
The number of patents filed for this field has increased by 27% annually from 2015 to 2019. Most patents for this technology were filed by Chinese applicants or inventors ahead of the United States, with Australia ranked 15th.
- China - 8248
- USA - 4937
- UK - 697
- Taiwan - 680
- R. of Korea - 584
- Australia - 185
Research institutions - international
The top 10 international institutions comprises a number of different countries, with Harvard University (United States) and the Institut national de la santé et de la recherche médicale (France) ranked closely in 1st and 2nd. The University of Melbourne (Australia) is ranked 10th.
|Rank||Top International Institution||Research Impact|
|1||Harvard University | United States||2960|
|2||Institut national de la santé et de la recherche médicale | France||2958|
|3||French National Centre for Scientific Research (CNRS) | France||2804|
|4||Chinese Academy of Sciences | China||2421|
|5||Imperial College London | United Kingdom||2200|
|6||University of Oxford | United Kingdom||2071|
|7||Spanish National Research Council (CSIC) | Spain||1820|
|8||National University of Singapore | Singapore||1670|
|9||National Institutes of Health | United States||1650|
|10||University of Melbourne | Australia||1565|
Research institutions - Australia
Australia has 5 universities in the top 50 international institutions. The University of Melbourne, the highest ranked Australian institute, ranks 10th internationally. The University of Queensland ranks 13th, University of Sydney 25th, University of New South Wales 32nd and Monash University 42nd.
|Rank||Top Australian Institution||Research Impact|
|1||University of Melbourne||1565|
|2||University of Queensland||1283|
|3||University of Sydney||1133|
|4||University of New South Wales||1011|
|6||Royal Brisbane and Women's Hospital||372|
|7||University of Adelaide||312|
|9||University of Western Australia||250|
Patents - Australia
|Top 5 Australian Patent Applicants||Patent Families|
|The University of Melbourne||10|
|University of Queensland||9|
|University of Sydney||7|
Patents filed by Australian businesses, 2015–2019.